Targeting Alpha-Synuclein: Breakthroughs in the Quest to Halt Parkinson's Progression

Parkinson's Disease Found to Have Clear Genetic Signature

Parkinson's vaccine effectively targets alpha-synuclein in Phase 1 trial, UB-312 reported to engage protein clumps, slow toxic buildup

Parkinson's Disease Therapies Targeting Alpha Synuclein

IJMS, Free Full-Text

Monthly Research Review: January 2022 – The Science of Parkinson's

Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology, Molecular Neurodegeneration

IJMS, Free Full-Text

New hopes for disease modification in Parkinson's Disease - ScienceDirect

Revisiting the specificity and ability of phospho-S129 antibodies to capture alpha-synuclein biochemical and pathological diversity

A Peptide Approach to Reducing alpha-Synuclein in Parkinson's Disease

What is coming in 2024 for Parkinson's Biological Definitions, Staging and Classification? — Parkinson Secrets

Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery

Peptide-based approaches to directly target alpha-synuclein in Parkinson's disease, Molecular Neurodegeneration